Pharmacodynamics and mechanism of action
The mechanism of action of primaquine makes it unique among electron transport inhibitors. The primary site of action and strict localization of the drug are plasmodial mitochondria (unlike the cytosol, apicoplast, or digestive vacuole of the parasite).
Pharmacodynamics is mediated through two key and interrelated mechanisms:
- Respiratory chain blockade. In the host body, the drug is metabolized to form an active compound — quinone. This metabolite has marked structural similarity to ubiquinone. Due to this, it competitively interferes with the functions of the parasite's endogenous ubiquinone, leading to a critical disruption of electron transport in the respiratory chain.
- Oxidative damage. An additional mechanism consists in non-specific oxidative damage to the plasmodial mitochondria. This damage is directly caused by drug metabolites toxic to the parasite, which accelerates energy starvation and the death of the pathogen.
Clinical application
In clinical practice, primaquine is used for a clearly defined purpose that distinguishes it from other antimalarial agents (such as chloroquine, mefloquine, or artemisinin).
- Target parasite stage: The drug is intended for the radical eradication of hepatic hypnozoites — the so-called «dormant» tissue forms of Plasmodium. It is not primarily targeted at erythrocytic schizonts, gametocytes, or sporozoites.
- Relapse prevention: The destruction of hypnozoites is the main condition for preventing long-term malaria relapses.
- Species specificity: The drug demonstrates high efficacy in malaria caused by specific species of the pathogen — Plasmodium vivax or Plasmodium ovale.
- Prophylactic use: In addition to treating an already developed disease, the agent can be successfully used as an independent prophylactic drug.
Contraindications and safety profile
The safety profile of primaquine requires careful monitoring, as the drug has a number of serious absolute contraindications and specific side effects.
Absolute contraindications:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Prescribing the drug to patients with a deficiency of this enzyme is strictly prohibited due to the extremely high risk of severe erythrocyte hemolysis.
- Pregnancy. The drug has the ability to freely cross the placental barrier. Since the fetus physiologically exhibits low G6PD enzyme activity, exposure to the drug can cause fatal hemolysis of fetal erythrocytes.
Adverse effects:
- Frequent reactions: Patients most frequently complain of gastrointestinal (GI) disorders.
- Hematological disorders: A characteristic complication of therapy is the development of methemoglobinemia.
- Rare reactions: In exceptional cases, neutropenia, neurological disorders (central nervous system), as well as cardiovascular system (CVS) disorders, including arterial hypertension and arrhythmias, may occur.
Chemical structure
For a deep understanding of pharmacology, it is important to navigate the chemical structure of antimalarial agents. A comparative analysis of the structural formulas of three key drugs reveals the following features:
- Primaquine: It is a typical 8-aminoquinoline derivative. It is this chemical structure that provides its ability to penetrate liver tissue and affect hypnozoites.
- Quinine: It is an alkaloid. Its molecule has a different structure and includes a quinoline ring joined to a quinuclidine fragment.
- Pyrimethamine: It belongs to a completely different chemical group and is a diaminopyrimidine derivative.
Briefly: answers to topical questions
What doses of primaquine are prescribed for the radical cure of malaria?
- Standard regimen — 45 mg (27 mg base) daily (3 tabl.) — 14-day course.
- Regimen for glucose-6-phosphate dehydrogenase (G6PD) deficiency — 6 tabl. once a week — 6–8 week course.
Remember the acronym PRIMA: Pepheric... hepatic hypnozoites (kills dormant forms), Relapses (prevents), Inhibitor of Mitochondria (disrupts electron transport), Aminoquinoline (8-aminoquinoline derivative).
Class and exam questions
Why is primaquine strictly contraindicated during pregnancy?
The drug easily crosses the placental barrier. Due to the physiologically low activity of the G6PD enzyme in the fetus, the drug's metabolites cause fatal hemolysis of its red blood cells.
Which stage of the Plasmodium life cycle does the drug act on?
Main target — hepatic hypnozoites («dormant» tissue forms). The drug is not intended for primary action on erythrocytic schizonts, gametocytes, or sporozoites.
What is the main mechanism of action at the cellular level?
The drug forms a metabolite (quinone) that structurally mimics ubiquinone. This leads to a competitive blockade of electron transport in the parasite's mitochondrial respiratory chain.
What else to study on this topic
- Comparative profile with chloroquine, mefloquine, and artemisinin
- Features of the chemical structure of quinine and pyrimethamine
- Pathogenesis of methemoglobinemia development when taking 8-aminoquinoline derivatives
- The role of the glucose-6-phosphate dehydrogenase (G6PD) enzyme in protecting erythrocytes from oxidative stress
- Life cycle of Plasmodium vivax and Plasmodium ovale: formation and activation of hypnozoites
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on «Primaquine» and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the "Drugs for protozoan infections" section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.